Concepedia

Author

Elisa Agostinetto

Université Libre de BruxellesORCID

Also Known As

Agostinetto, Elisa, C Molinelli, E Agostinetto, E. Agostinetto, Elisa Agostinetto

190

Publications

2.6K

Citations

25

H-Index

22

Concepts

All Affiliations

Université Libre de BruxellesInstitut Jules BordetIstituti di Ricovero e Cura a Carattere ScientificoOspedale Policlinico San MartinoHumanitas University
EA

About

Elisa Agostinetto is an author at Université Libre de Bruxelles specializing in oncology, medicine, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

97

2

Education

1

1

14

3

Cell Biology

1

1

31

4

Health Promotion

1

1

14

5

Obstetrics

1

1

31

Elisa Agostinetto

×

25

Publications

783

Citations

15

H-Index

YearCitations

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Elisa Agostinetto, Mattia Rediti, Danai Fimereli,

Cancers

2021

268

Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse

Frédéric Cailleux, Elisa Agostinetto, Matteo Lambertini,

JCO Precision Oncology

2022

72

Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto,

JAMA

2023

49

Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar

Elisa Agostinetto, Giuseppe Curigliano, Martine Piccart

Cell Reports Medicine

2024

31

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

Eva Blondeaux, Amir Sonnenblick, Elisa Agostinetto,

The Lancet Oncology

2025

31

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

Raffaella Palumbo, Rosalba Torrisi, Federico Sottotetti,

Therapeutic Advances in Medical Oncology

2021

25

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Matteo Lambertini, Eva Blondeaux, Giancarlo Bisagni,

EClinicalMedicine

2023

23

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Laurence Buisseret, Delphine Loirat, Philippe Aftimos,

Nature Communications

2023

23

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani,

npj Breast Cancer

2023

22

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

Evandro de Azambuja, Elisa Agostinetto, Marion Procter,

ESMO Open

2023

21

Page 1